LL-37: The Human Cathelicidin Antimicrobial Peptide in Immune Research

For informational purposes only. This article does not constitute medical advice. Consult a qualified healthcare provider for any health-related decisions.

What Is LL-37?

LL-37 is the sole cathelicidin antimicrobial peptide produced by the human body. Its name derives from its structural characteristics: it begins with two leucine residues (LL) and consists of 37 amino acids in total. LL-37 is generated by proteolytic cleavage of the 18-kDa precursor protein hCAP-18 (human cationic antimicrobial protein 18) by the serine protease proteinase 3 in neutrophils or by other proteases in epithelial tissues and skin.

As a host defense peptide, LL-37 is expressed in neutrophils, monocytes, macrophages, mast cells, natural killer cells, and various epithelial surfaces including skin, the respiratory tract, the gastrointestinal tract, and the urogenital system. It is a central effector molecule of the innate immune system, serving as a first line of defense against microbial invasion while simultaneously orchestrating broader immune responses. LL-37 has emerged as one of the most intensively studied peptides in immune-modulating peptide research.

Property	Detail
Full Name	LL-37 (Leucine-Leucine-37)
Precursor	hCAP-18 (human cationic antimicrobial protein 18)
Length	37 amino acids
Molecular Weight	~4,493 Da
Structure	Alpha-helical, amphipathic, cationic (+6 net charge)
Gene	CAMP (cathelicidin antimicrobial peptide)
Expressed In	Neutrophils, monocytes, macrophages, epithelial cells, keratinocytes
Processing Enzyme	Proteinase 3 (neutrophils); kallikreins (skin)
Vitamin D Regulation	Yes — VDRE in CAMP gene promoter
Regulatory Status	Endogenous peptide; synthetic forms in research/clinical development

Mechanism of Action: Multifaceted Host Defense

Direct Antimicrobial Activity

LL-37's antimicrobial mechanism centers on its amphipathic alpha-helical structure. The peptide adopts a helical conformation in membrane-like environments, presenting a hydrophobic face and a cationic face. This structure allows LL-37 to selectively interact with microbial membranes, which are rich in anionic phospholipids (phosphatidylglycerol, cardiolipin, and lipopolysaccharide), while showing relatively lower affinity for mammalian cell membranes, which are composed primarily of zwitterionic phospholipids (phosphatidylcholine, sphingomyelin).

Several models describe how LL-37 disrupts microbial membranes:

• Toroidal pore model: LL-37 molecules insert into the membrane and induce lipid curvature, forming toroidal pores that allow leakage of intracellular contents
• Carpet model: At higher concentrations, LL-37 accumulates on the membrane surface in a carpet-like fashion until a threshold is reached, at which point the membrane disintegrates
• Intracellular targeting: Beyond membrane disruption, internalized LL-37 can bind bacterial DNA and RNA, inhibiting transcription and translation

Biofilm Disruption

One of LL-37's most clinically relevant properties is its ability to affect bacterial biofilms. Biofilms are structured microbial communities encased in an extracellular matrix that renders them highly resistant to conventional antibiotics — often requiring 100 to 1,000 times higher antibiotic concentrations than planktonic (free-floating) bacteria. LL-37 affects biofilms through several mechanisms:

• Prevention of initial bacterial attachment to surfaces at sub-antimicrobial concentrations
• Disruption of quorum sensing signaling systems that coordinate biofilm formation
• Degradation of extracellular matrix components
• Promotion of twitching motility in Pseudomonas aeruginosa, causing bacteria to move away rather than form sessile communities
• Penetration of established biofilms to kill embedded bacteria

This anti-biofilm activity has generated particular interest because biofilm-associated infections (chronic wounds, prosthetic joint infections, catheter-associated infections, chronic sinusitis) represent a major unmet clinical need.

Immunomodulatory Functions

Beyond its direct antimicrobial role, LL-37 serves as a sophisticated immune signaling molecule:

• Chemotaxis: LL-37 acts as a chemoattractant for neutrophils, monocytes, and T cells through activation of the formyl peptide receptor-like 1 (FPRL1/FPR2), recruiting immune cells to sites of infection
• Anti-endotoxin activity: LL-37 binds and neutralizes lipopolysaccharide (LPS), reducing the risk of septic shock from gram-negative infections
• Dendritic cell modulation: LL-37 influences dendritic cell differentiation and maturation, bridging innate and adaptive immune responses
• Angiogenesis: LL-37 promotes new blood vessel formation, which is important for wound healing and tissue repair
• Cytokine modulation: Context-dependent regulation of pro-inflammatory and anti-inflammatory cytokine production, helping to fine-tune the inflammatory response
• NET formation: LL-37 can promote neutrophil extracellular trap (NET) formation, an antimicrobial mechanism where neutrophils release web-like structures of DNA and antimicrobial proteins to trap and kill pathogens

The Vitamin D Connection

A critically important aspect of LL-37 biology is its regulation by vitamin D. The CAMP gene encoding hCAP-18 (LL-37's precursor) contains a vitamin D response element (VDRE) in its promoter region. When vitamin D binds to the vitamin D receptor (VDR), the activated receptor complex binds to this VDRE and upregulates CAMP gene transcription, increasing LL-37 production. This direct transcriptional link between vitamin D status and innate antimicrobial defense has provided a mechanistic explanation for epidemiological observations linking vitamin D deficiency to increased susceptibility to infections, particularly respiratory infections and tuberculosis.

Research Landscape

Infectious Disease Applications

LL-37 and its analogs are being investigated for several infectious disease applications:

• Chronic wound infections: Topical LL-37 has shown promise in clinical-stage research for diabetic foot ulcers and venous leg ulcers, where biofilm-associated infections impair healing
• Respiratory infections: Inhaled LL-37 formulations are under investigation for multidrug-resistant pulmonary infections
• Catheter-associated infections: LL-37-coated medical devices to prevent biofilm formation on catheters and implants
• Antibiotic synergy: LL-37 shows synergistic activity with conventional antibiotics, potentially enabling lower antibiotic doses and reducing resistance development

Wound Healing Research

LL-37 promotes wound healing through multiple mechanisms beyond infection control: stimulating keratinocyte migration, promoting angiogenesis, and modulating the inflammatory-to-proliferative phase transition. A phase I/II clinical trial of topical LL-37 (marketed in research contexts as OP-145 or related analogs) for hard-to-heal venous leg ulcers reported encouraging preliminary results, though larger confirmatory trials are needed.

Cancer Biology

LL-37's role in cancer is complex and context-dependent. In some cancers (ovarian, breast, lung), LL-37 overexpression has been associated with tumor progression through its pro-angiogenic and cell-proliferative effects. In other cancers (gastric, colon, hematological malignancies), LL-37 has shown anti-tumor activity through membrane disruption of cancer cells and immune activation. This dual nature underscores the complexity of host defense peptide biology and highlights that therapeutic applications must be carefully designed with consideration of the disease context.

Safety Considerations

As an endogenous human peptide, LL-37 at physiological concentrations is inherently part of normal immune function. However, therapeutic applications using exogenous LL-37 introduce several safety considerations:

• Hemolytic activity: At high concentrations, LL-37 can damage mammalian cell membranes, including red blood cells. Therapeutic formulations must balance antimicrobial efficacy against host cell toxicity.
• Pro-inflammatory potential: Excessive LL-37 activity has been implicated in inflammatory conditions including psoriasis (where LL-37 forms complexes with self-DNA that activate plasmacytoid dendritic cells through TLR9), rosacea, and atherosclerosis.
• Cancer complexity: The dual pro-tumorigenic and anti-tumorigenic effects of LL-37 mean that systemic administration requires careful risk assessment.
• Stability and cost: LL-37 is susceptible to proteolytic degradation in biological environments and is expensive to synthesize at 37 amino acids, driving research toward shorter, more stable analogs.
• Resistance potential: While antimicrobial peptide resistance develops more slowly than antibiotic resistance, bacterial mechanisms for LL-37 resistance have been identified, including membrane modification and protease secretion.

Comparisons with Other Immune Peptides

Feature	LL-37	Thymosin Alpha-1	Defensins (HBD-1/2/3)
Class	Cathelicidin	Thymic peptide	Defensin family
Length	37 amino acids	28 amino acids	29-45 amino acids
Primary Function	Direct antimicrobial + immunomodulation	Immunomodulation (T-cell, DC, NK)	Direct antimicrobial + chemotaxis
Biofilm Activity	Strong anti-biofilm effects	Not a primary function	Moderate
Vitamin D Regulated	Yes (VDRE in promoter)	No	Some defensins are
Clinical Stage	Phase I/II (analogs)	Approved in 35+ countries	Preclinical (therapeutic use)

Current Research Status and Outlook

LL-37 research is among the most active areas in immune-modulating peptide science. The compound's multifunctionality — combining direct antimicrobial activity, biofilm disruption, immune recruitment, wound healing promotion, and anti-endotoxin effects — makes it a uniquely versatile platform for therapeutic development. The growing crisis of antibiotic resistance has further intensified interest in host defense peptides as alternative or adjunctive antimicrobial strategies.

The principal challenges for LL-37 therapeutic development include production cost (37-amino-acid peptide synthesis is expensive at scale), proteolytic instability in biological fluids, and the need to separate beneficial antimicrobial/immune effects from potentially harmful pro-inflammatory or pro-tumorigenic activities in certain contexts. Much current research focuses on developing shorter, more stable LL-37 analogs and mimetics that retain the desired biological activities while addressing these limitations.

The vitamin D/LL-37 axis also continues to attract attention as a public health consideration, as widespread vitamin D insufficiency may contribute to impaired innate immune defenses through reduced LL-37 production. This connection has implications for understanding susceptibility to respiratory infections, tuberculosis, and other infectious diseases.

This article is for educational and informational purposes only. Synthetic LL-37 is not approved as a standalone therapeutic for human use. Nothing in this article should be interpreted as an endorsement of, or recommendation to use, this compound outside of supervised clinical research.